葛根素治疗溃疡性结肠炎的研究进展
Research Progress on the Treatment of Ulcerative Colitis with Puerarin
DOI: 10.12677/hjmce.2026.143024, PDF,    科研立项经费支持
作者: 王亚宁, 尹鹏举, 苏 阳, 梁 喆, 郎需坤, 张博文：济宁医学院临床医学院，山东 济宁；邵骏菁*：济宁医学院基础医学院，山东 济宁
关键词: 葛根素；溃疡性结肠炎；作用机制；临床研究；Puerarin； Ulcerative Colitis； Mechanism of Action； Clinical Research
摘要: 溃疡性结肠炎(Ulcerative Colitis, UC)是一种慢性、复发性的非特异性肠道炎症性疾病，其发病机制复杂。当前主流治疗药物存在副作用大、长期疗效有限及价格昂贵等局限性。因此，寻找高效、低毒的天然活性成分成为研究热点。葛根素是从传统中药葛根中提取的主要异黄酮类活性成分，大量研究表明，其通过多靶点、多通路发挥抗炎、抗氧化、保护肠道屏障及调节肠道菌群等作用，在溃疡性结肠炎的研究中展现出良好的应用前景。文章系统综述了葛根素治疗溃疡性结肠炎的潜在作用机制及临床研究，并对其未来研究方向进行展望，为临床治疗UC提供新思路和新方向。
Abstract: Ulcerative colitis (UC) is a chronic and recurrent non-specific inflammatory disease of the intestinal tract, with a complex pathogenesis. The current mainstream therapeutic drugs have limitations such as significant side effects, limited long-term efficacy, or high prices. Therefore, the search for efficient and low-toxic natural active components has become a research hotspot. Puerarin is the main isoflavone active component extracted from the traditional Chinese medicine Codonopsis pilosula. A large number of studies have shown that it exerts anti-inflammatory, antioxidant, and protective effects on the intestinal barrier and regulation of the intestinal flora through multiple targets and pathways. The research on ulcerative colitis shows good application prospects. This article systematically reviews the potential mechanism of action and clinical studies of genistein in the treatment of ulcerative colitis, and looks forward to its future research directions, providing new ideas and directions for the clinical treatment of UC.
文章引用：王亚宁, 尹鹏举, 苏阳, 梁喆, 郎需坤, 张博文, 邵骏菁. 葛根素治疗溃疡性结肠炎的研究进展[J]. 药物化学, 2026, 14(3): 244-250. https://doi.org/10.12677/hjmce.2026.143024

参考文献

[1] Kaenkumchorn, T. and Wahbeh, G. (2020) Ulcerative Colitis: Making the Diagnosis. Gastroenterology Clinics of North America, 49, 655-669.
https://doi.org/10.1016/j.gtc.2020.07.001
[2] Hracs, L., Windsor, J.W., Gorospe, J., Cummings, M., Coward, S., Buie, M.J., et al. (2025) Global Evolution of Inflammatory Bowel Disease across Epidemiologic Stages. Nature, 642, 458-466.
https://doi.org/10.1038/s41586-025-08940-0
[3] Porter, R.J., Kalla, R. and Ho, G.T. (2020) Ulcerative Colitis: Recent Advances in the Understanding of Disease Pathogenesis. F1000Research, 9, 294.
https://doi.org/10.12688/f1000research.20805.1
[4] Wangchuk, P., Yeshi, K. and Loukas, A. (2024) Ulcerative Colitis: Clinical Biomarkers, Therapeutic Targets, and Emerging Treatments. Trends in Pharmacological Sciences, 45, 892-903.
https://doi.org/10.1016/j.tips.2024.08.003
[5] 陈子怡, 常彩虹, 马荣泽, 等. 葛根及其药对研究进展[J/OL]. 中华中医药学刊, 1-20.
https://link.cnki.net/urlid/21.1546.R.20260116.1528.030, 2026-01-28.
[6] Wang, D., Bu, T., Li, Y., He, Y., Yang, F. and Zou, L. (2022) Pharmacological Activity, Pharmacokinetics, and Clinical Research Progress of Puerarin. Antioxidants, 11, Article No. 2121.
https://doi.org/10.3390/antiox11112121
[7] Aebisher, D., Bartusik-Aebisher, D., Przygórzewska, A., Oleś, P., Woźnicki, P. and Kawczyk-Krupka, A. (2024) Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies. International Journal of Molecular Sciences, 26, Article No. 121.
https://doi.org/10.3390/ijms26010121
[8] Neurath, M.F. (2024) Strategies for Targeting Cytokines in Inflammatory Bowel Disease. Nature Reviews Immunology, 24, 559-576.
https://doi.org/10.1038/s41577-024-01008-6
[9] Olbei, M., Hautefort, I., Thomas, J.P., Csabai, L., Bohar, B., Koigi, S.S., et al. (2026) Decoding Cytokine Networks in Ulcerative Colitis to Identify Pathogenic Mechanisms and Therapeutic Targets. Science Signaling, 19, eadt0986.
https://doi.org/10.1126/scisignal.adt0986
[10] Sahoo, D.K., Heilmann, R.M., Paital, B., Patel, A., Yadav, V.K., Wong, D., et al. (2023) Oxidative Stress, Hormones, and Effects of Natural Antioxidants on Intestinal Inflammation in Inflammatory Bowel Disease. Frontiers in Endocrinology (Lausanne), 14, Article ID: 1217165.
https://doi.org/10.3389/fendo.2023.1217165
[11] Wan, Y., Yang, L., Jiang, S., Qian, D. and Duan, J. (2022) Excessive Apoptosis in Ulcerative Colitis: Crosstalk between Apoptosis, ROS, ER Stress, and Intestinal Homeostasis. Inflammatory Bowel Diseases, 28, 639-648.
https://doi.org/10.1093/ibd/izab277
[12] Arumugam, P., Saha, K. and Nighot, P. (2025) Intestinal Epithelial Tight Junction Barrier Regulation by Novel Pathways. Inflammatory Bowel Diseases, 31, 259-271.
https://doi.org/10.1093/ibd/izae232
[13] Capaldo, C.T. (2023) Claudin Barriers on the Brink: How Conflicting Tissue and Cellular Priorities Drive IBD Pathogenesis. International Journal of Molecular Sciences, 24, Article No. 8562.
https://doi.org/10.3390/ijms24108562
[14] Ning, L., Zhou, Y.L., Sun, H., Zhang, Y., Shen, C., Wang, Z., et al. (2023) Microbiome and Metabolome Features in Inflammatory Bowel Disease via Multi-Omics Integration Analyses across Cohorts. Nature Communications, 14, Article No. 7135.
https://doi.org/10.1038/s41467-023-42788-0
[15] Han, T., Zhang, Y., Zheng, G. and Guo, Y. (2025) From Pathogenic Mechanisms to Therapeutic Perspectives: A Review of Gut Microbiota and Intestinal Mucosal Immunity in Inflammatory Bowel Disease. Frontiers in Immunology, 16, Article ID: 1704651.
https://doi.org/10.3389/fimmu.2025.1704651
[16] López-Siles, M., Camprubí-Font, C., Gómez del Pulgar, E.M., Sabat Mir, M., Busquets, D., Sanz, Y., et al. (2022) Prevalence, Abundance, and Virulence of Adherent-Invasive Escherichia Coli in Ulcerative Colitis, Colorectal Cancer, and Coeliac Disease. Frontiers in Immunology, 13, Article ID: 748839.
https://doi.org/10.3389/fimmu.2022.748839
[17] Pandey, H., Jain, D., Tang, D.W.T., Wong, S.H. and Lal, D. (2024) Gut Microbiota in Pathophysiology, Diagnosis, and Therapeutics of Inflammatory Bowel Disease. Intestinal Research, 22, 15-43.
https://doi.org/10.5217/ir.2023.00080
[18] Li, X., Wang, Y., Wang, K., et al. (2020) Puerarin Alleviates Ulcerative Colitis in Mice by Suppressing NF-κB and MAPK Signaling Pathways. Chinese Journal of Natural Medicines, 18, 674-683.
[19] Jeon, Y.D., Lee, J.H., Lee, Y.M. and Kim, D.K. (2020) Puerarin Inhibits Inflammation and Oxidative Stress in Dextran Sulfate Sodium-Induced Colitis Mice Model. Biomedicine & Pharmacotherapy, 124, Article ID: 109847.
https://doi.org/10.1016/j.biopha.2020.109847
[20] 赵鑫, 陈旭涛, 鲁星妤, 等. 葛根素抑制巨噬细胞NLRP3炎症小体表达减轻溃疡性结肠炎及其初步机制分析[J]. 中国免疫学杂志, 2025, 41(4): 775-782.
[21] Murakami, S., Kusano, Y., Okazaki, K., Akaike, T. and Motohashi, H. (2023) NRF2 Signalling in Cytoprotection and Metabolism. British Journal of Pharmacology, 183, 101-114.
https://doi.org/10.1111/bph.16246
[22] Lin, C., Zhou, Z., Zhang, L., Wang, H., Lu, J., Wang, X., et al. (2026) Gegen Qinlian Decoction Relieves Ulcerative Colitis via Adjusting Dysregulated Nrf2/ARE Signaling. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID: 2934552.
https://doi.org/10.1155/2022/2934552
[23] Tao, Q., Liang, Q., Fu, Y., Qian, J., Xu, J., Zhu, Y., et al. (2024) Puerarin Ameliorates Colitis by Direct Suppression of Macrophage M1 Polarization in DSS Mice. Phytomedicine, 135, Article ID: 156048.
https://doi.org/10.1016/j.phymed.2024.156048
[24] Wu, Y., Li, Y., Ruan, Z., Li, J., Zhang, L., Lu, H., et al. (2020) Puerarin Rebuilding the Mucus Layer and Regulating Mucin-Utilizing Bacteria to Relieve Ulcerative Colitis. Journal of Agricultural and Food Chemistry, 68, 11402-11411.
https://doi.org/10.1021/acs.jafc.0c04119
[25] 但文利, 赵鑫, 鲁星妤, 等. 基于网络药理学及实验验证探究葛根素治疗溃疡性结肠炎的作用机制[J]. 中国免疫学杂志, 2024, 40(5): 1055-1063.
[26] Zou, Y., Ding, W., Wu, Y., Chen, T. and Ruan, Z. (2023) Puerarin Alleviates Inflammation and Pathological Damage in Colitis Mice by Regulating Metabolism and Gut Microbiota. Frontiers in Microbiology, 14, Article ID: 1279029.
https://doi.org/10.3389/fmicb.2023.1279029
[27] Yin, Y., Yang, T., Tian, Z., Shi, C., Yan, C., Li, H., et al. (2025) Progress in the Investigation of the Firmicutes/Bacteroidetes Ratio as a Potential Pathogenic Factor in Ulcerative Colitis. Journal of Medical Microbiology, 74, Article No. 10.
https://doi.org/10.1099/jmm.0.001966
[28] 王宇婷, 廖家明, 朱磊. 中药调控Nrf2相关信号通路防治溃疡性结肠炎的研究进展[J]. 时珍国医国药, 2025, 36(18): 3537-3545.
[29] Li, Q., Cui, Y., Xu, B., Wang, Y., Lv, F., Li, Z., et al. (2021) Main Active Components of Jiawei Gegen Qinlian Decoction Protects against Ulcerative Colitis under Different Dietary Environments in a Gut Microbiota-Dependent Manner. Pharmacological Research, 170, Article ID: 105694.
https://doi.org/10.1016/j.phrs.2021.105694
[30] 许会平, 吴琼, 李丹丹. 加味葛根芩连汤治疗中重度溃疡性结肠炎效果[J]. 承德医学院学报, 2026, 43(1): 32-36.
[31] 解晓帅, 董运茁, 穆殿平, 等. 葛根素注射液临床使用安全性的评价研究[J]. 中国中药杂志, 2018, 43(19): 3956-3961.
[32] 潘洪平. 葛根素的吸收动力学及对脑缺血损伤的保护作用研究[D]: [博士学位论文]. 武汉: 华中科技大学, 2010.
[33] 李伟平, 张喜平. 葛根素制剂的药理和临床应用及存在问题分析[J]. 医学研究杂志, 2012, 41(1): 16-18+141.
[34] Liu, X., 王盈. 载葛根素的聚乙二醇化介孔二氧化硅纳米粒的体内外评价[J]. 中国医药工业杂志, 2016, 47(11): 1435.
[35] 代丽萍, 李维, 卓虹伊, 等. 基于Ⅰ相代谢调控的葛根素微乳的制备及其药动学研究[J]. 中国药房, 2019, 30(11): 1459-1464.
[36] Fan, Q., Kan, C., Wang, K., Zhu, H., Zhang, Y., Lu, M., et al. (2026) Oral Colon Targeted Curcumin-Based Nanocomposite Inulin Hydrogel for Alleviating Intestinal Inflammation and Dysbiosis. Journal of Nanobiotechnology, 24, Article No. 408.
https://doi.org/10.1186/s12951-026-04318-0